Contents
10 February 2021
Vol 13, Issue 580
Vol 13, Issue 580
Research Articles
- Percutaneous liquid ablation agent for tumor treatment and drug delivery
An ionic liquid formulation ablates tumors, uniformly distributes drugs in the ablation zone, and has synergistic effects with chemotherapy.
- Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Incorporating TLR9-inhibitory sequences in the AAV vector genome inhibits immunogenicity and enhances transgene expression in multiple animal models.
- Human neurons from Christianson syndrome iPSCs reveal mutation-specific responses to rescue strategies
Neurons from patient-derived iPSCs demonstrate mutation-specific responses to potential therapeutic strategies for Christianson syndrome.
- Targeted immunotherapy for HER2-low breast cancer with 17p loss
Trastuzumab conjugated to α-amanitin kills HER2-low breast cancer cells with loss of chromosome 17p and enhances checkpoint blockade therapy.
- Nicotinamide for the treatment of heart failure with preserved ejection fraction
The NAD+ precursor nicotinamide improves diastolic dysfunction caused by aging, hypertension, or metabolic syndrome in rodents.
- Loss of TGFβ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types
The impact of TGFβ signaling on DNA repair competency is observed in a pan-cancer analysis of survival after treatments that cause DNA damage.
- Paroxetine-mediated GRK2 inhibition is a disease-modifying treatment for osteoarthritis
G protein–coupled receptor kinase 2 is increased in OA, and inhibition by the antidepressant paroxetine prevents disease progression.
Review
- Cell type–specific microRNA therapies for myocardial infarction
microRNA-based therapies for myocardial infarction have opportunities and limitations on the basis of the target cell type and molecular pathways.
Erratum
About The Cover
ONLINE COVER Locoregional Liquid Ablation. This illustration shows a liquid ablation agent being injected into a tumor in the liver under ultrasound imaging guidance. Albadawi et al. developed an injectable ionic liquid that killed tumor cells in rat hepatocellular carcinoma and rabbit hepatic tumor models. The agent also ablated tumors when injected into resected human tumor tissue ex vivo and enabled uniform distribution of co-injected dyes or chemotherapeutics. Use of this liquid ablation agent as a locoregional therapy could help bridge patients with hepatocellular carcinoma to liver transplant. [CREDIT: MIKE AUSTIN/INTERNAL ART MEDICAL ILLUSTRATION]
